Intrinsic resistance to EGFR tyrosine kinase inhibitors in advanced non-small-cell lung cancer with activating EGFR mutations

Identifying activating EGFR mutations is a useful predictive strategy that helps select a population of advanced non-small-cell lung cancer (NSCLC) patients for treatment with EGFR tyrosine kinase inhibitors (TKIs). Patients with sensitizing EGFR mutations (predominantly an in-frame deletion in exon...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jun, Wang, Baocheng, Chu, Huili, Yao, Yunfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922765/
https://www.ncbi.nlm.nih.gov/pubmed/27382309
http://dx.doi.org/10.2147/OTT.S106399

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4922765/
https://www.ncbi.nlm.nih.gov/pubmed/27382309
http://dx.doi.org/10.2147/OTT.S106399

Ejemplares similares